v3.25.2
Segment Information - Summary of significant segment expenses and segment net loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]              
Canvuparatide direct program expense $ 8,923   $ 4,980   $ 17,260 $ 8,963  
Imapextide direct program expense 987   5,108   2,793 7,744  
MBX 4291 direct program expense 2,547   1,521   8,322 2,145  
Preclinical and other research and development direct expense 1,641   358   2,850 575  
Research and development overhead expense 3,626   2,429   8,905 6,018  
Other segment items [1] 1,687   1,461   3,161 2,749  
Net loss $ 19,411 $ 23,880 $ 15,857 $ 12,337 $ 43,291 $ 28,194 $ 61,900
[1]

(1) Other segment items are primarily comprised of general and administrative expenses and interest and other income.